Skip Navigation


Hum. Reprod. Advance Access originally published online on January 21, 2005
Human Reproduction 2005 20(5):1200-1206; doi:10.1093/humrep/deh741
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/5/1200    most recent
deh741v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Griesinger, G.
Right arrow Articles by Felberbaum, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griesinger, G.
Right arrow Articles by Felberbaum, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions{at}oupjournals.org

Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol

G. Griesinger1, A. Schultze-Mosgau, K. Dafopoulos, A. Schroeder, A. Schroer, S. von Otte, D. Hornung, K. Diedrich and R. Felberbaum

University Clinic of Schleswig Holstein, Campus Luebeck, Ratzeburger Allee 160, 23858 Luebeck, Germany

1 To whom correspondence should be addressed: Email: georg.griesinger{at}frauenklinik.uni-luebeck.de

BACKGROUND: Suppression of endogenous LH production by mid-follicular phase GnRH-antagonist administration in controlled ovarian hyperstimulation protocol using recombinant (rec) FSH preparations void of LH activity may potentially affect ovarian response and the outcome of IVF treatment. The present study prospectively assessed the effect of using a combination of recFSH and recLH on ovarian stimulation parameters and treatment outcome in a fixed GnRH-antagonist multiple dose protocol. METHODS: 127 infertile patients with an indication for IVF or ICSI were recruited and randomized (using sealed envelopes) to receive a starting dose of either 150 IU recFSH (follitropin {alpha}) or 150 IU recFSH plus 75 IU recLH (lutropin {alpha}) for ovarian hyperstimulation. GnRH-antagonist (Cetrorelix) 0.25 mg was administered daily from stimulation day 6 onwards up to and including the day of the administration of recombinant HCG (chorion gonadotropin {alpha}). Gonadotropin dose adjustments were allowed from stimulation day 6 onwards, HCG was administered as soon as three follicles ≥18 mm were present. The primary outcome parameter was treatment duration until administration of HCG. RESULTS: Exogenous LH did not shorten the time necessary to reach ovulation induction criteria. Serum estradiol (E2) and LH levels were significantly higher on the day of HCG administration in the recLH-supplemented group (1924.7 ± 1256.4 vs 1488.3 ± 824.0 pg/ml, P<0.03), and 2.1 ± 1.4 vs 1.4 ± 1.5 IU/l, P<0.01, respectively). CONCLUSIONS: Except for higher E2 and LH levels on the day of HCG administration, no positive trend in favour of additional LH was found as defined by treatment outcome parameters.

Key words: cetrorelix/GnRH-antagonist/ovarian stimulation/recombinant FSH/recombinant LH


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
E. Bosch, C. Vidal, E. Labarta, C. Simon, J. Remohi, and A. Pellicer
Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study
Hum. Reprod., June 25, 2008; (2008) den220v1.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E.M. Kolibianakis, L. Kalogeropoulou, G. Griesinger, E.G. Papanikolaou, J. Papadimas, J. Bontis, and B.C. Tarlatzis
Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis
Hum. Reprod. Update, September 1, 2007; 13(5): 445 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen
GnRH antagonists in ovarian stimulation for IVF
Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E.M. Kolibianakis, J. Collins, B. Tarlatzis, E. Papanikolaou, and P. Devroey
Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review
Hum. Reprod. Update, January 1, 2006; 12(1): 3 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E.M. Kolibianakis, A. Schultze-Mosgau, A. Schroer, A. van Steirteghem, P. Devroey, K. Diedrich, and G. Griesinger
A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists
Hum. Reprod., October 1, 2005; 20(10): 2887 - 2892.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.